within Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA07_FoslevodopaAndDecarboxylaseInhib;

model FoslevodopaAndDecarboxylaseInhib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.3611111111111111e-05,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0012,
    k12 = 1.1666666666666666e-05,
    k21 = 1.1666666666666666e-05);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>FoslevodopaAndDecarboxylaseInhibitor</td></tr><tr><td>ATC code:</td><td>N04BA07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Foslevodopa is a phosphate prodrug of levodopa developed to provide continuous dopaminergic stimulation for the management of Parkinson's disease, co-administered with a decarboxylase inhibitor to reduce peripheral levodopa metabolism. The drug is under clinical development and not yet generally approved for clinical use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data available for foslevodopa and decarboxylase inhibitor combination in humans. Parameters below are not experimentally determined but estimated based on general properties of levodopa prodrugs and intravenous/oral levodopa administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N04BA07 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end FoslevodopaAndDecarboxylaseInhib;
